Diagenode

>>>   Click for Diagenode’s approach to COVID-19

Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes.


Nassiri F, Chakravarthy A, Feng S, Shen SY, Nejad R, Zuccato JA, Voisin MR, Patil V, Horbinski C, Aldape K, Zadeh G, De Carvalho DD

Definitive diagnosis of intracranial tumors relies on tissue specimens obtained by invasive surgery. Noninvasive diagnostic approaches provide an opportunity to avoid surgery and mitigate unnecessary risk to patients. In the present study, we show that DNA-methylation profiles from plasma reveal highly specific signatures to detect and accurately discriminate common primary intracranial tumors that share cell-of-origin lineages and can be challenging to distinguish using standard-of-care imaging.

Tags
MagMeDIP kit
Antibody

Share this article

Published
June, 2020

Source

Products used in this publication

  • RFX5-polyclonal-antibody-diagenode
    C15200081-100
    5-methylcytosine (5-mC) monoclonal antibody 33D3
  • MagMeDIP qPCR Kit box
    C02010021
    MagMeDIP qPCR kit

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics